**Core tip:** In the diagnostic of focal pancreatic lesions, several studies showed a good value of Contrast enhanced endoscopic ultrasound (CEH-EUS) in detecting pancreatic adenocarcinoma, while less is known about other focal pancreatic pathologies. In our retrospective cohort, we can confirm the good value of CEH-EUS for the detection of pancreatic adenocarcinoma. We additionally show the high value of instant qualitative evaluation of CEH-EUS images in everyday routine as well as the limitations of quantitative analyses, making precise quantification dispensable. Moreover, we describe perfusion characteristics of several other solid pancreatic masses of different origin.

INTRODUCTION
============

After its first introduction in 1980, endoscopic ultrasound (EUS) has been established as an effective tool in the diagnostic of intestinal organs. With ongoing technical development image resolution has advanced and ultrasound guided fine needle aspiration (EUS-FNA) opened the chance to cytological assessment of suspicious lesions. In particular identification and evaluation of pancreatic solid and cystic masses as well as their relationship to adjacent vessels and organs have improved through EUS techniques\[[@B1]\].

However, the precise discrimination between benign and malignant pancreatic lesions remains often difficult, amongst other reasons due to non-diagnostic cytological results or misguided fine needle aspirates. Early detection of malignancies is crucial, as surgery is the only potential curative treatment. Unfortunately, both EUS and EUS-FNA lack sufficient accuracy, leading to false positive and false negative results in up to one fifth of cases\[[@B2]-[@B5]\].

Surgery should be carried out as soon as possible in malignant lesions due to rapid disease progression. As morbidity and mortality of pancreatic surgery are high, it is crucial to identify benign pancreatic or non-adenocarcinoma lesions\[[@B6],[@B7]\].

Contrast enhanced ultrasound has been shown to be a helpful tool in transabdominal ultrasound. There is increasing experience with benign and malignant masses of the liver, kidney and other solid organs, as well as neoplastic, inflammatory and ischemic lesions *e.g*., in the intestine\[[@B8]-[@B12]\].

Ultrasound contrast agents contain microbubbles filled with gas surrounded by a shell. In harmonic imaging, low acoustic energies with a mechanical index between 0.1 and 0.06 lead to an oscillation of microbubbles in harmonic frequencies, which enhances the scattered ultrasound signal. Moreover, low acoustic energies allow subtraction of the tissue-derived ultrasound signals. As the microbubbles do not leave the microvasculature, this leads to improved detectability of arteries, veines, microvessels and blood perfusion characteristics in different perfusion phases\[[@B13]\].

Sensitivity of transabdominal ultrasound of the pancreas is often limited, mostly due to meteorism. Accuracy of EUS in detection of pancreatic lesions is significantly better\[[@B14],[@B15]\].

New echo-endoscopes allow the use of ultrasound contrast agents in harmonic EUS imaging\[[@B16],[@B17]\].

In some studies, the value of contrast enhanced EUS in the diagnostic of pancreatic masses has been evaluated\[[@B18]-[@B23]\], showing good diagnostic value. This was in principally reached with the help of time consuming quantitative ultrasound data analysis later on.

With this study, we want to determine the diagnostic value of qualitative, immediately analysed contrast enhanced harmonic EUS (CEH-EUS) in comparison with precise quantitative analyses for the diagnostic of various pancreatic masses in daily routine in a single centre cohort.

MATERIALS AND METHODS
=====================

Data of all patients with undetermined solid pancreatic masses who underwent EUS procedures with application of contrast agent was included in the retrospective analysis. Patients with predominantly cystic pancreatic lesions were not included.

Video documented data sets of CEH-EUS investigations of these patients were evaluated. All investigations have been performed during clinical routine procedures.

Investigations were carried out as follows: Standard B-mode EUS was performed in all patients with suspected pancreatic masses. If undetermined masses were found, size, location and echogenicity were documented. The patient underwent CEH-EUS if no contraindications, including, age under 18 years, pregnancy, lactation, severe heart failure, severe chronic obstructive pulmonary disease, known allergic disposition to SonoVue^®^, were present.

CEH-EUS was performed as follows: Numerous patients with focal pancreatic lesions undergoing EUS investigations in our facility from April 2011 till September 2016 received 5mL SonoVue (Bracco s.p.a., Milan, Italy) *via* cubital vein catheter, followed by a saline flush. The echoendoscope used was Hitachi/Pentax EG3670URK or EG3870UTK (Hitachi Medical Corp., Tokyo, Japan) the ultrasound processor Hitachi Preirus (Hitachi Medical Corp., Tokyo, Japan). Observation of the pancreatic lesion was performed for at least one minute after SonoVue^®^ injection.

The investigator was not blinded to the previous history of each patient. First clinical evaluation of qualitative contrast agent characteristics (hypoenhanced, isoenhanced, hyperenhanced or non-enhanced) was performed immediately by the investigator upon the endoscopic procedure and documented in the physician's report. Investigations were carried out by TK, RM, KK and CM, blinded video data analysis later on was performed by KK; all investigators had several years of experience with both EUS and contrast enhanced ultrasound.

Ultrasound video sequences were continuously recorded and then analysed later on, using the analysis software of the ultrasound processor (Hitachi Preirus). This software allows quantification of ultrasound signal intensity over time in regions of interest, which are defined by the analysing physician.

Analysis of the recorded video data included arrival time (AT), time to peak (TTP), maximum intensity gain and area under the curve. To rule out circulation time error, two regions of interest were defined; one in the suspicious pancreatic lesion, one in pancreatic tissue besides the lesion. Hypoenhancement was defined as signal intensity of at least 5 db below, hyperenhancement as signal intensity of at least 5 db above the intensity of the pancreatic tissue surrounding the lesion.

In all patients EUS-FNA, transcutaneous biopsy or surgical resection was performed to allow cytology or histology assessment, which served as the gold standard.

For statistical analyses calculation of means and standard deviations as well as sensitivitiy, specificity, positive and negative predictive values were carried out with the help of SPSS SigmaPlot, V.10.0.0.54. Predictive values were calculated on the basis of the investigated cohort.

As a retrospective analysis, institutional review board approval was seen not to be necessary by the local ethics committee. However, all patients signed informed consent for the investigations and for the contrast agent application.

RESULTS
=======

Data sets of 55 patients were analysed. The mean patient age was 66.5 ± 12.5 years (range: 24-83 years). 32 patients were male and 23 patients were female.

Of those 55 patients, CEH-EUS showed hypoenhanced lesions in 39 cases, while in 13 patients contrast agent characteristics were classified as hyperenhanced by the investigator upon investigation and 3 lesions as non-enhanced. Calculation of signal intensity later on showed signal intensity of 6.1 ± 3.2 db for lesions classified as hypoenhanced and 39.0 ± 13.0 db for lesions classified as hyperenhanced. Non-enhanced lesions showed signal intensity of 1.3 ± 0.3 db (Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics

                               **Hypoenhanced lesions**   **Hyperenhanced lesions**   **Σ**
  ---------------------------- -------------------------- --------------------------- -------------
  Patient age (yr)             72.1 ± 6.7                 66.7 ± 15.3                 66.5 ± 12.5
  Gender (m/f)                 23/19                      9/4                         32/23
  Lesion size (mm)             34.8 ± 13.7                36.0 ± 15.6                 35.1 ± 14.0
  Peak signal intensity (db)   6.1 ± 3.2                  39.0 ± 13.0                 

db: Decibel.

Endosonographic healthy appearing pancreatic tissue showed signal intensity of 23.1 ± 9.1 db.

Concordance of the investigators evaluation and classification of contrast enhancement with precise analysis later on was found to be 100%.

Regarding hypoenhanced lesions, 34 lesions with low contrast enhancement were proven as pancreatic adenocarinoma (intensity 5.7 ± 2.5 db) and in 5 patients chronic pancreatitis lesions showed up hypoenhanced (6.0 ± 3.0 db). Those patients remained under endosonographic follow up including FNA. Figure [1](#F1){ref-type="fig"} shows an example of time intensity curves of pancreatic adenocarcinoma compared to healthy pancreatic tissue. All non-enhanced lesions showed up as necrosis of the pancreas.

![During contrast enhanced harmonic endoscopic ultrasound procedures patients received 5 mL SonoVue^®^ contrast agent. The figure shows an example of ultrasound signal intensity curves of healthy pancreatic tissue and pancreatic adenocarcinoma.](WJCC-7-19-g001){#F1}

Hyperenhanced lesions were of inflammatory origin in 4 cases (1 patient with autoimmune pancreatitis, 3 patients with active chronic pancreatitis) showing signal intensity of 34.0 ± 11.9 db, in 3 patients due to neuroendocrine carcinoma (33.0 ± 12.0 db), in 1 case a lymphoma (45 db), in 1 case an insulinoma (29 db) and in 4 patients metastases, of which 2 were of renal cell carcinoma and 2 of lung cancer, was diagnosed (56.0 ± 5.6 db). Figure [2](#F2){ref-type="fig"} shows ultrasound images of hyperenhanced neuroendocrine carcinoma and pancreatic adenocarcinoma.

![Contrast enhanced harmonic endoscopic ultrasound images of hypoenhanced pancreatic adenocarcinoma and hyperenhancement of neuroendocrine carcinoma. A: Contrast enhanced harmonic endoscopic ultrasound (CEH-EUS) images of hypoenhanced pancreatic adenocarcinoma; B: CEH-EUS images of neuroendocrine carcinoma. TU: Tumor left side.](WJCC-7-19-g002){#F2}

Sensitivity for the detection of pancreatic adenocarcinoma was 100%, specificity 73.6% for low contrast agent enhancement alone. Taking also standard EUS evaluation of the whole pancreas into account, all hypoenhanced lesions in otherwise endosonographically healthy appearing pancreatic tissue were pancreatic adenocarcinoma (sensitivity and specificity 100%). In our cohort, positive predictive value for pancreatic adenocarcinoma was 87.2% for contrast agent characteristics alone, taking native tissue characteristics into account 100%. Negative predictive value was 100% in both cases. Statistics of inflammatory and neoplastic lesions are given in Table [2](#T2){ref-type="table"}.

###### 

Statistics

                                             **Peak intensity (db)**   **Sensitivity**   **Specifity**   **PPV**   **NPV**
  ------------------------------------------ ------------------------- ----------------- --------------- --------- ---------
  Hypoenhanced lesions                                                                                             
  Adenocarcinoma (all in healthy pancreas)   5.7 ± 2.5                 100%              100%            100%      100%
  Chronic pancreatitis lesions               6.0 ± 3.0                 100%              23.30%          13%       100%
  Hyperenhanced lesions                                                                                            
  Acute inflammatory lesions                 34.0 ± 11.9               100%              79.10%          30.80%    81.70%
  Neoplastic lesions                         32.1 ± 10.2               20.90%            55.50%          69.20%    12.80%

PPV: Positive predictive value; NPV: Negative predictive value; db: Decibel.

The analysis of further contrast agent characteristics \[area under the time intensity curve (AUC), TTP, AT\] did not yield helpful results in everyday routine; in 13 hypoenhanced lesions calculation of these parameters was impossible due to low contrast enhancement. In 5 cases data sets of areas used as reference in macroscopic normal appearing tissue could not be analysed for these parameters, mostly due to breathing artefacts. While analysis of AT and TTP did not show clear differences between any lesions and their reference areas, AUC analysis, where possible, showed the same tendency as the maximum peak intensity data, but suffered from substantial interindividual differences and did therefore not improve the diagnostic value (Table [3](#T3){ref-type="table"}).

###### 

Quantitative analysis of different perfusion parameters

  **Lesion**                  **AT lesion (s)**   **AT non-lesion (s)**   **TTP lesion (s)**   **TTP non-lesion (s)**   **AUC lesion (db × s)**   **AUC non-lesion (db × s)**   **PI lesion (db)**   **PI non-lesion (db)**
  --------------------------- ------------------- ----------------------- -------------------- ------------------------ ------------------------- ----------------------------- -------------------- ------------------------
  Pancreatic adenocarcinoma   11.70 ± 3.87        11.49 ± 3.26            20.58 ± 4.89         22.41 ± 6.52             238.52 ± 150.63           912.34 ± 359.40               5.77 ± 2.54          21.6 ± 8.6
  (*n* = 25/34)               (*n* = 31/34)       (*n* = 25/34)           (*n* = 31/34)        (*n* = 25/34)            (*n* = 31/34)             (*n* = 34/34)                 (*n* = 34/34)        
  Chronic pancreatitis        11.92 ± 4.61        11 ± 1.00               22.42 ± 4.83         22.33 ± 1.52             424.41 ± 188.83           681.96 ± 216.22               13.5 ± 12.0          22.0 ± 5.8
  (*n* = 4/8)                 (*n* = 6/8)         (*n* = 4/8)             (*n* = 6/8)          (*n* = 4/8)              (*n* = 6/8)               (*n* = 8/8)                   (*n* = 8/8)          
  Neuroendocrine Carcinoma    10.2 ± 1.98         10.0 ± 1.41             22.00 ± 1.41         20.50 ± 0.70             1410.80 ± 535.56          855.55 ± 190.14               31 ± 8.3             20.3 ± 7.5
  (*n* = 3)                   (*n* = 3)           (*n* = 3)               (*n* = 3)            (*n* = 3)                (*n* = 3)                 (*n* = 3/3)                   (*n* = 3/3)          
  Metastases (RCC / LC)       10.00 ± 2.82        10.5 ± 2.12             30 ± 14.14           31.00 ± 15.55            2941.95 ± 1067.51         1081.40 ± 1096.43             56.0 ± 5.6           31.5 ± 2.1
  (*n* = 2/2)                 (*n* = 2/2)         (*n* = 2/2)             (*n* = 2/2)          (*n* = 2/2)              (*n* = 2/2)               (*n* = 2/2)                   (*n* = 2/2)          
  Immune-pancreatitis         12                  12                      21                   22                       77032                     6036                          28                   16
  (*n* = 1)                   (*n* = 1)           (*n* = 1)               (*n* = 1)            (*n* = 1)                (*n* = 1)                 (*n* = 1)                     (*n* = 1)            
  Lymphoma                    6                   8                       11                   19                       1570.7                    913.1                         45                   28
  (*n* = 1)                   (*n* = 1)           (*n* = 1)               (*n* = 1)            (*n* = 1)                (*n* = 1)                 (*n* = 1)                     (*n* = 1)            
  Insulinoma                  13                  13                      23                   23                       721.0                     802.0                         16                   18
  (*n* = 1)                   (*n* = 1)           (*n* = 1)               (*n* = 1)            (*n* = 1)                (*n* = 1)                 (*n* = 1)                     (*n* = 1)            

AT: Arrival time; TTP: Time to peak intensity; AUC: Area under the curve; PI: Peak intensity; RCC: Renal cell carcinoma; LC: Lung cancer; db: Decibel.

With the limitations of a retrospective analysis no side effects of contrast agent application were documented.

DISCUSSION
==========

In the present study, we assessed the value of the qualitative, immediate analysis of CEH-EUS in the diagnostic of solid pancreatic lesions in comparison to precise and time consuming quantitative processing.

As shown above, CEH-EUS had an excellent diagnostic value if hypoenhanced lesions were detected. Of those lesions located in healthy pancreatic tissue all were diagnosed with pancreatic adenocarcinoma, making cytology results possibly dispensable, especially in the case of resectable lesions preoperatively, thereby reducing the risk for complications *e.g*., bleeding, infection, or causing local tumor cell seeding. Especially in case of nondiagnostic FNA results, hypoenhanced masses in otherwise healthy pancreatic tissue could be surgically resected without further efforts of cytology sampling.

Accuracy was independent from patient characteristics such as gender, age, comorbidities and tumor size. As harmonic imaging technique, CEH-EUS offers better image resolution than power doppler imaging of suspicious lesions.

While in some other studies quantitative evaluations were helpful\[[@B21],[@B24]\], our data shows the value of this technique in everyday routine by the investigators immediate evaluation of contrast agent characteristics without complex and time consuming image analysis after the actual examination. Moreover, precise quantitative assessment including AUC analysis was of no better value than both measurement of ultrasound signal intensity and qualitative contrast enhancement evaluation during the investigations.

Despite some recent studies\[[@B24]-[@B26]\] the value of CEH-EUS to distinguish chronic pancreatitis lesions from malignancies was very limited in our cohort, as on the one hand also benign chronic inflammatory lesions showed up hypoenhanced, on the other hand active inflammation resulted in stronger contrast enhancement. Especially with the increased risk of malignancies in patients with chronic pancreatitis, accurate diagnostic tools are needed, and at least in our hands CEH-EUS alone showed an unsatisfactory sensitivity and specificity. This suggests that in abnormal pancreatic tissue, CEH-EUS still does not offer sufficient accuracy to exclude malignancies, which makes EUS-FNA essential.

The low perfusion of both chronic pancreatitis lesions and pancreatic adenocarcinoma can be explained through the stromal richness of both lesions with only few capillaries. Possibly, EUS elastography of the pancreas may be able to distinguish these lesions from each other\[[@B27],[@B28]\], while data is still limited.

Looking at hyperenhanced lesions, various pathologies including metastases could be detected. This makes histologic or cytologic sampling essential for further treatment and diagnosis.

Diagnostic tools should be easily accessable, quick and easy to apply and safe while showing reliable and reproducible results. Regarding side effects, none were documented in this retrospective analysis, which is consistent with the general experience of SonoVue^®^ application. Although not exactly measured, contrast agent application required only a few extra minutes of investigation and sedation time.

In a prospective analysis, Gincul et al\[[@B29]\] could show that various perfusion parameters which were analysed after CEH-EUS procedures showed good correlation with the diagnosis of pancreatic adenocarcinoma, which is confirmed by our data. Taking time effectiveness into account, initial evaluation of the contrast agent behaviour was consistent with precise analysis later on. Further calculation of ultrasound data later on does not increase the diagnostic value and therefore does not appear to be necessary, making the contrast enhancement evaluation easy and quick.

EUS itself has become a standard procedure for the diagnostic of intestinal diseases, offering better image resolutions and fewer limitations like meteorism. Although risk of intestinal injury is slightly increased, EUS is in general a well-tolerated and fast spreading technique also with the elderly patients\[[@B1],[@B30]\].

Although it has become a routine procedure, biopsy sampling *via* EUS-FNA sometimes lacks diagnostic accuracy\[[@B3],[@B31]\], showing false negative and sometimes false positive results while there is the risk of bleeding and infectious complications in addition to a low but potential risk of local seeding of tumor cells\[[@B32]-[@B35]\].

Patient safety could therefore be increased and treatment costs could be reduced if patients with potentially resectable hypoenhanced lesions could be preoperatively diagnosed in an outpatient setting without cytologic sampling while those with hyperenhanced lesions definitely require further diagnostics as surgery might not be the optimal choice of treatment.

In conclusion, CEH-EUS showed good diagnostic accuracy, especially in case of hypoenhanced lesions. If situated in healthy pancreatic lesions, pancreatic adenocarcinoma is highly suspicious and patients may be sent for surgical resection without further cytology assessment. In case of hyperenhanced lesions, cytology or histology are crucial for guiding further treatment, as a variety of pathologies may show up with hyperenhancement.

In our hands, CEH-EUS showed excellent results also using qualitative analysis of contrast agent characteristics without complicated and time consuming analyses of ultrasound data later on, proving its value for everyday routine practice.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

While some studies have shown that quantitative analysis of contrast enhanced endoscopic ultrasound (CEH-EUS) helps to identify pancreatic adenocarcinoma, there are less data from everyday routine. For non-adenocarcinoma lesions, less information of contrast agent characteristics has been published so far.

Research motivation
-------------------

As in pancreatic malignancies surgery is the only potential cure, quick and efficient diagnostics are needed to guide further therapy and avoid unnecessary delay. As biopsy sampling from fine needle aspiration (EUS-FNA) requires diagnostics in an inpatient setting, alternative methods with good diagnostic accuracy would make outpatient diagnostics possible, which would be both time saving and less expensive.

Research objectives
-------------------

The main research objective was to show the value of CEH-EUS in the daily routine diagnostic of various pancreatic lesions. Besides the hypoenhancement of pancreatic adenocarcinoma, which was quantitatively shown before, various other pancreatic lesions warrent future research.

Research methods
----------------

CEH-EUS data of 55 patients with solid pancreatic lesions were analysed regarding contrast agent characteristics. Statistical analysis of time to peak, peak intensity, area under the time intensity curve, arrival time were compared to qualitative evaluation during the investigation, while histological specimen or FNA results served as gold standard.

Research results
----------------

All pancreatic adenocarcinoma showed up hypoenhanced, while several other lesions including metases of other origin, lymphoma and inflammatory lesions showed up hyperenhanced. Quantitative analysis oft he EUS data did not add any value to the qualitative evaluation. Moreover, calculation of the quantitative parameters was in some cases difficult, among others due to low signal intensity in hypoenhanced lesions or due to moving artifacts.

Research conclusions
--------------------

Qualitative evaluation of contrast agent characteristics is sufficient to identify pancreatic adenocarcinoma in healthy pancreatic tissue and could make EUS-FNA in patients with resectable disease dispensable. Hyperenhanced pancreatic lesions can be of various origin, which makes histological sampling essential.

Research perspectives
---------------------

Especially for hyperenhanced pancreatic lesions, prospective studies are needed to broaden the experience with this intersting technique. Possibly, algorythms with different techniques such as CEH-EUS and EUS-elastography could further help to classify pancreatic masses in difficult situations such as chronic pancreatitis patients.
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